Examkin

Soru

Zorluk: OrtaHematology and Oncology

An emergency department evaluation is requested for a 3434-year-old woman due to continuous gingival bleeding, recurrent epistaxis, and extensive bruising that began two days ago. She has felt profoundly fatigued for the last week. Vital signs include a temperature of 37.4∘C37.4^{\circ}\text{C} (99.3∘F99.3^{\circ}\text{F}), blood pressure of 110/70 mmHg110/70\text{ mmHg}, heart rate of 105/min105/\text{min}, and respiratory rate of 18/min18/\text{min}. Examination shows diffuse petechiae on both lower extremities and active mucosal oozing in the oropharynx.

Laboratory results are as follows:

TestResult
Hemoglobin8.2 g/dL8.2\text{ g/dL}
Leukocyte count24,000/μL24,000/\mu\text{L}
Platelet count18,000/μL18,000/\mu\text{L}
Prothrombin time22 sec22\text{ sec}
Activated partial thromboplastin time45 sec45\text{ sec}
Fibrinogen85 mg/dL85\text{ mg/dL} (normal: 150−400 mg/dL150-400\text{ mg/dL})

A review of the peripheral blood smear reveals an abundance of atypical promyelocytes, many of which contain bundles of needle-like intracytoplasmic inclusions.

Arrange the following evaluation and management steps in the most appropriate chronological sequence for this patient.

  1. 1Administer all-trans retinoic acid (ATRA)
  2. 2Perform bone marrow aspiration and biopsy for genetic analysis
  3. 3Initiate induction chemotherapy with an anthracycline or arsenic trioxide
  4. 4Monitor for and manage symptoms of differentiation syndrome

Cevap

The correct sequence of steps is: 1) Administer all-trans retinoic acid, 2) Perform bone marrow aspiration and biopsy, 3) Initiate induction chemotherapy, and 4) Monitor for differentiation syndrome.
The management of acute promyelocytic leukemia (APL) requires a specific sequential approach due to its unique pathophysiology. APL frequently presents with severe disseminated intravascular coagulation (DIC), which can lead to fatal hemorrhage. Therefore, the absolute first step upon suspecting APL from a peripheral smear is the immediate administration of all-trans retinoic acid (ATRA). ATRA induces differentiation of the leukemic promyelocytes, rapidly reversing the coagulopathy. This must occur before a definitive bone marrow biopsy is obtained. Once the patient is stabilized and ATRA is initiated, a bone marrow aspiration and biopsy are performed to confirm the presence of the t(15;17) translocation or PML-RARA fusion gene. After confirmation, induction chemotherapy (such as arsenic trioxide with or without an anthracycline) is added to the regimen for definitive treatment. Finally, throughout the treatment course, clinicians must monitor for differentiation syndrome, a potentially life-threatening complication of ATRA characterized by fever, hypoxemia, and pulmonary infiltrates, which is managed with dexamethasone.

Adım Adım Çözüm

1
Identify the primary diagnosis from the clinical presentation.
The patient has pancytopenia, laboratory evidence of disseminated intravascular coagulation (DIC), and atypical promyelocytes with Auer rods, which is highly characteristic of acute promyelocytic leukemia (APL).
Recognizing APL is a critical medical emergency because of the high risk of fatal bleeding from DIC.
2
Determine the most urgent initial intervention.
Administer all-trans retinoic acid (ATRA) immediately.
ATRA forces the differentiation of leukemic promyelocytes and rapidly improves the associated life-threatening coagulopathy. It should not be delayed for bone marrow confirmation.
3
Determine the subsequent steps for definitive diagnosis and treatment.
Perform bone marrow biopsy, followed by initiation of induction chemotherapy.
Once the patient is stabilized on ATRA, genetic confirmation via bone marrow biopsy (t(15;17)) is required, followed by definitive induction therapy (e.g., arsenic trioxide and/or an anthracycline).
4
Identify anticipated treatment complications.
Monitor for differentiation syndrome.
As leukemic cells mature in response to ATRA, patients can develop differentiation syndrome (fever, pulmonary infiltrates, weight gain), which requires prompt recognition and treatment with dexamethasone.

Anahtar Kavram

In patients with suspected acute promyelocytic leukemia (APL) presenting with disseminated intravascular coagulation, all-trans retinoic acid (ATRA) must be administered immediately based on peripheral smear findings, prior to definitive bone marrow confirmation, to prevent fatal hemorrhage.
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Hematology and Oncology

Bu konudan daha fazla soru